These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 36711984)

  • 1. Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants.
    Addetia A; Piccoli L; Case JB; Park YJ; Beltramello M; Guarino B; Dang H; Pinto D; Scheaffer S; Sprouse K; Bassi J; Silacci-Fregni C; Muoio F; Dini M; Vincenzetti L; Acosta R; Johnson D; Subramanian S; Saliba C; Giurdanella M; Lombardo G; Leoni G; Culap K; McAlister C; Rajesh A; Dellota E; Zhou J; Farhat N; Bohan D; Noack J; Lempp FA; Cameroni E; Whitener B; Giannini O; Ceschi A; Ferrari P; Franzetti-Pellanda A; Biggiogero M; Garzoni C; Zappi S; Bernasconi L; Kim MJ; Schnell G; Czudnochowski N; Franko N; Logue JK; Yoshiyama C; Stewart C; Chu H; Schmid MA; Purcell LA; Snell G; Lanzavecchia A; Diamond M; Corti D; Veesler D
    bioRxiv; 2023 Feb; ():. PubMed ID: 36711984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization, effector function and immune imprinting of Omicron variants.
    Addetia A; Piccoli L; Case JB; Park YJ; Beltramello M; Guarino B; Dang H; de Melo GD; Pinto D; Sprouse K; Scheaffer SM; Bassi J; Silacci-Fregni C; Muoio F; Dini M; Vincenzetti L; Acosta R; Johnson D; Subramanian S; Saliba C; Giurdanella M; Lombardo G; Leoni G; Culap K; McAlister C; Rajesh A; Dellota E; Zhou J; Farhat N; Bohan D; Noack J; Chen A; Lempp FA; Quispe J; Kergoat L; Larrous F; Cameroni E; Whitener B; Giannini O; Cippà P; Ceschi A; Ferrari P; Franzetti-Pellanda A; Biggiogero M; Garzoni C; Zappi S; Bernasconi L; Kim MJ; Rosen LE; Schnell G; Czudnochowski N; Benigni F; Franko N; Logue JK; Yoshiyama C; Stewart C; Chu H; Bourhy H; Schmid MA; Purcell LA; Snell G; Lanzavecchia A; Diamond MS; Corti D; Veesler D
    Nature; 2023 Sep; 621(7979):592-601. PubMed ID: 37648855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Expression of the Recombinant Spike Receptor Binding Domain of SARS-CoV-2 Omicron in the Periplasm of
    Kim WS; Kim JH; Lee J; Ka SY; Chae HD; Jung I; Jung ST; Na JH
    Bioengineering (Basel); 2022 Nov; 9(11):. PubMed ID: 36354581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping.
    Shah M; Woo HG
    Front Mol Biosci; 2023; 10():1236617. PubMed ID: 37828918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
    Cameroni E; Saliba C; Bowen JE; Rosen LE; Culap K; Pinto D; VanBlargan LA; De Marco A; Zepeda SK; Iulio JD; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà P; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Veesler D; Snell G; Corti D
    bioRxiv; 2021 Dec; ():. PubMed ID: 34931194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo.
    Ikemura N; Taminishi S; Inaba T; Arimori T; Motooka D; Katoh K; Kirita Y; Higuchi Y; Li S; Suzuki T; Itoh Y; Ozaki Y; Nakamura S; Matoba S; Standley DM; Okamoto T; Takagi J; Hoshino A
    Sci Transl Med; 2022 Jun; 14(650):eabn7737. PubMed ID: 35471044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
    Shah M; Woo HG
    Front Immunol; 2021; 12():830527. PubMed ID: 35140714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markov State Models and Perturbation-Based Approaches Reveal Distinct Dynamic Signatures and Hidden Allosteric Pockets in the Emerging SARS-Cov-2 Spike Omicron Variants Complexes with the Host Receptor: The Interplay of Dynamics and Convergent Evolution Modulates Allostery and Functional Mechanisms.
    Xiao S; Alshahrani M; Gupta G; Tao P; Verkhivker G
    bioRxiv; 2023 May; ():. PubMed ID: 37292827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1.
    Geng Q; Shi K; Ye G; Zhang W; Aihara H; Li F
    J Virol; 2022 Apr; 96(8):e0024922. PubMed ID: 35343765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5.
    Entzminger KC; Fleming JK; Entzminger PD; Espinosa LY; Samadi A; Hiramoto Y; Okumura SCJ; Maruyama T
    Antib Ther; 2023 Apr; 6(2):108-118. PubMed ID: 37324547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant.
    Sokal A; Broketa M; Barba-Spaeth G; Meola A; Fernández I; Fourati S; Azzaoui I; de La Selle A; Vandenberghe A; Roeser A; Bouvier-Alias M; Crickx E; Languille L; Michel M; Godeau B; Gallien S; Melica G; Nguyen Y; Zarrouk V; Canoui-Poitrine F; Noizat-Pirenne F; Megret J; Pawlotsky JM; Fillatreau S; Simon-Lorière E; Weill JC; Reynaud CA; Rey FA; Bruhns P; Chappert P; Mahévas M
    Immunity; 2022 Jun; 55(6):1096-1104.e4. PubMed ID: 35483354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
    Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
    Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
    Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
    Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.